Emtriva researcher prepares to launch new biotech

One of the researchers involved in Emory University's record-setting $525 million licensing deal for the HIV drug Emtriva plans to use part of his cut to set up a new bioscience company in Atlanta. Raymond Schinazi says he plans to spend about $12 million to start RFS Pharma, which will concentrate on developing antiviral and anti-cancer drugs. Another biotech company started by Schinazi, Pharmasset, recently announced plans to move to Princeton, New Jersey.

- read this report from the Atlanta Business Chronicle for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.